Overview

Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer

Status:
Completed

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with irinotecan, 5-FU and leucovorin in the second-line treatment of subject with metastatic colorectal cancer

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Bevacizumab
Calcium
Calcium, Dietary
Camptothecin
Fluorouracil
Irinotecan
Leucovorin
Levoleucovorin
Pharmaceutical Solutions